To the best of our knowledge, this is the first study showing association of ABCG2 Q141K (rs2231142), SLC29A3 S158F (rs780668) and POLR2A N764K (rs2228130) with NSCLC patient outcome treated with gemcitabine-based chemotherapy. This evidence concerns the gene POLR2A and non-small cell lung carcinoma.